Lori Hazlehurst has been named as the associate director for Basic Research at the WVU Cancer Institute. In this role, she will work closely with Richard Goldberg, Institute director, and the leadership team of the WVU Cancer Institute to implement strategic goals to increase the impact of basic and translational cancer research at WVU. The primary strategy is to increase the number of NIH funded investigators focused on cancer research at WVU.
Eli Lilly and Co. and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo Oncology for $235 per share in cash, or approximately $8 billion.
Nanobiotix and MD Anderson Cancer Center announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal, and genitourinary cancers.
Adaptive Biotechnologies and Genentech said they have entered into a worldwide collaboration and license agreement to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.
Maureen Testoni has been named as the 340B Health CEO by the e 340B Health board of directors.
The NCI Board of Scientific Advisors approved five Requests for Applications, as well as two Cancer Moonshot concepts, at a joint meeting with the National Cancer Advisory Board on Dec. 4, 2018.
I have had the privilege of accepting young men and women into medical oncology fellowship programs at Memorial Sloan Kettering Cancer Center, the University of Vermont Cancer Center and MD Anderson Cancer Center and I have watched many of them shine as they took on both academic and community oncology positions throughout the United States and the world.Waun Ki Hong was special.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
AstraZeneca and Merck said FDA has approved Lynparza for use as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
FDA has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.
